

Management of Complex Adverse Events: Case Studies

Brianna Hoffner, MSN, ANP-BC, AOCNP



#SITC2016



NOVEMBER 9-13, 2016

Disclosures

None



#SITC2016





- 58 year old female with IV melanoma with metastases to the liver and bone
- PMH: Hypertension, Hypercholesterolemia, Asthma
- PSH: Cholecystectomy
- Initiated on Ipilimumab (3mg/kg) + Nivolumab (1mg/kg)
 - C1D1 7/1/16
 - C2D1 7/22/16
 - C3D1 8/19/16





- 8/27/16 patient presents to outside hospital complaining of fever, cough and shortness of breath
- VS: BP 125/86, HR 90, RR 22, O2 90%, Temp 100.1
- CXR: Read as RML pneumonia
- Patient initiated on amoxicillin 875mg/125mg Q12







- 8/30/16 patient presents to clinic with continued low grade fever, cough and diarrhea since 8/29/16
- Denies sick contacts, dietary changes
- Approximately 8 loose bowel movements per day (baseline 1 BM daily)
- No relief with loperamide
- Cough making it difficult to sleep at night



Case #1

GASTROINTESTINAL Page 2 of								
		Grade						
Adverse Event	Short Name	1	2	3	4	5		
Diarrhea	Diarrhea	Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline	Increase of 4 – 6 stools per day over baseline; IV fluids indicated <24hrs; moderate increase in ostomy output compared to baseline; not interfering with ADL	Increase of ≥7 stools per day over baseline; incontinence; IV fluids ≥24 hrs; hospitalization; severe increase in ostomy output compared to baseline; interfering with ADL	Life-threatening consequences (e.g., hemodynamic collapse)	Death		
REMARK: Diarrhea includes diarrhea of small bowel or colonic origin, and/or ostomy diarrhea.								
ALSO CONSIDER: Dehydration; Hypotension.								

PULMONARY/UPPER RESPIRATORY						age 1 of 4	
		Grade					
Adverse Event	Short Name	1	2	3	4	5	
Cough	Cough	Symptomatic, non- narcotic medication only indicated	Symptomatic and narcotic medication indicated	Symptomatic and significantly interfering with sleep or ADL	_	—	
Pneumonitis/pulmonary infiltrates	Pneumonitis	Asymptomatic, radiographic findings only	Symptomatic, not interfering with ADL	Symptomatic, interfering with ADL; O ₂ indicated	Life-threatening; ventilatory support indicated	Death	
ALSO CONSIDER: Adult Respiratory Distress Syndrome (ARDS); Cough; Dyspnea (shortness of breath); Hypoxia; Infection (documented clinically or microbiologically) with Grade 3 or 4 neutrophils (ANC <1.0 x 10 ⁹ /L) – Select; Infection with normal ANC or Grade 1 or 2 neutrophils – Select; Infection with unknown ANC – Select; Pneumonitis/pulmonary infiltrates; Pulmonary fibrosis (radiographic changes).							

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE




- Grade 3 Diarrhea Differential Diagnoses:
 - Infectious diarrhea (including c-diff)
 - Antibiotic associated diarrhea
 - Colitis secondary to immunotherapy
- Grade 3 Cough v Pneumonitis Differential Diagnoses:
 - Infectious
 - Inflammatory
 - Irritation




Case #1

Chest CT scan:



Abdominal CT scan:



ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE





- Grade 3 Colitis and Grade 3 Pneumonitis
 - Initiate steroid at 1mg/kg of solumedrol or equivalent
 - Recommend IV steroid initially with colitis symptoms due to gut absorption issues
 - Taper slowly
 - Consider antibiotic prophylaxis during high dose steroid
 - Discontinue immunotherapy





- 35 year old man with classic Hodgkin's lymphoma
 - Autologous stem cell transplant 1/25/16
 - Brentuximab Vedotin (Adcetris) 5/1/16-8/1/16
 - Relapsed disease noted on 8/1/16 scans
 - 8/8/16 initiated on Nivolumab 3mg/kg Q2 weeks





- 10/3/16 patient presents for C5D1 complaining of fatigue and decreased appetite
 - Denies nausea, vomiting or diarrhea
 - Denies abdominal pain
 - Denies fevers or chills but states "I get cold easily"
 - States that his fatigue does not improve with rest





CONSTITUTIONAL SYMPTOMS Page 1 of 2						
		Grade				
Adverse Event	Short Name	1	2	3	4	5
Fatigue (asthenia, lethargy, malaise)	Fatigue	Mild fatigue over baseline	Moderate or causing difficulty performing some ADL	Severe fatigue interfering with ADL	Disabling	—

- Grade 2 Fatigue Differential Diagnosis:
 - Anemia
 - Hepatitis
 - Hypothyroidism
 - Hypophysitis
 - Disease progression
 - Poor sleep quality
 - Infection





- Labs 10/3/16:
 - Hgb: 10.5 (12.1-16.3 g/dL) (baseline Hgb 10.9)
 - LDH: 261 (124-271 U/L)
 - **TSH:** 8.4 (0.34-5.6 mlU/L)
 - **T3:** 1.7 (*2.3-4.2 pg/ml*)
 - **T4:** 0.53 (0.89-1.76 ng/dL)
 - AST: 38 (12-39 U/L)
 - ALT: 50 (7-52 U/L)
 - **Tbili:** 0.5 (0.1-1.3 mg/dL)
 - Alk Phos: 105 (39-117 U/L)



Case #2

		Investigation	IS					
Grade								
Adverse Event	1	2	3	4	5			
Alanine aminotransferase increased	>ULN - 3.0 x ULN	>3.0 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN	-			
Definition: A finding based on l	aboratory test results that indicat	te an increase in the level of alar	nine aminotransferase (ALT or S	GPT) in the blood specimen.				
Alkaline phosphatase increased	>ULN - 2.5 x ULN	>2.5 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN	-			
Definition: A finding based on l	aboratory test results that indicat	te an increase in the level of alka	line phosphatase in a blood spe	cimen.				
Aspartate aminotransferase increased	>ULN - 3.0 x ULN	>3.0 - 5.0 x ULN	>5.0 - 20.0 x ULN	>20.0 x ULN	-			
Definition: A finding based on l	aboratory test results that indicat	te an increase in the level of asp	artate aminotransferase (AST or	SGOT) in a blood specimen.				
Blood bilirubin increased	>ULN - 1.5 x ULN	>1.5 - 3.0 x ULN	>3.0 - 10.0 x ULN	>10.0 x ULN	-			
Definition: A finding based on la	aboratory test results that indicat	e an abnormally high level of bili	rubin in the blood. Excess bilirub	in is associated with jaundice.				

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE





ENDOCRINE						age 2 of 2
		Grade				
Adverse Event	Short Name	1	2	3	4	5
Thyroid function, low (hypothyroidism)	Hypothyroidism	Asymptomatic, intervention not indicated	Symptomatic, not interfering with ADL; thyroid replacement indicated	Symptoms interfering with ADL; hospitalization indicated	Life-threatening myxedema coma	Death

- Grade 2 Hypothyroidism
 - Initiate Levothyroxine at 1.7 mcg/kg PO daily
 - Consider referral to endocrinology
 - Council patient that this may not be reversible
 - OK to continue treatment with Nivolumab